Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2016 -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Linda Grais, M.D., Chief Executive Officer, will be presenting at the upcoming Stifel 2016 Healthcare Conference being held November 15-16, 2016 at the Lotte New York Palace Hotel in New York, New York. Ocera’s presentation will take place on November 16, 2016 at 11:45 AM Eastern Time.
A live audio webcast of the presentation will be available in the "Investors" section of Ocera's website, www.ocerainc.com. A replay of the presentation will be available for 60 days following the conference for those unable to listen live.
About Ocera
Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate) in both intravenous and oral formulations. OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute-on-chronic liver disease. For additional information, please see www.ocerainc.com.
OCRX-G
Contact:
Susan Sharpe
Ocera Therapeutics, Inc.
[email protected]
919-328-1109
